Quarterly report pursuant to Section 13 or 15(d)

Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details)

v3.23.2
Revenue - Collaboration Agreement - The GSK and Transfer Agreement (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2023
GBP (£)
Jun. 30, 2023
USD ($)
Jun. 30, 2023
USD ($)
Apr. 06, 2023
USD ($)
Apr. 06, 2023
GBP (£)
Revenue          
Revenue recognized in the period     $ 52,046,000    
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   $ 318,107,000 318,107,000    
GSK Termination and Transfer Agreement          
Revenue          
Upfront payment received | £ £ 7,500,000        
Potential milestone payments to be received | £ £ 22,500,000        
Amount of transaction price of the agreement at inception       $ 37,335,000  
Upfront and milestone payment receivable | £         £ 30,000,000
Revenue recognized in the period   0 0    
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   37,857,000 37,857,000    
IGNYTE          
Revenue          
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   21,200,000 21,200,000    
LTFU          
Revenue          
Aggregate amount of the transaction price that is allocated to performance obligations that are unsatisfied or partially satisfied under the agreements   $ 16,657,000 $ 16,657,000